Studies Continue on COVID-19 Vaccines in Children Younger Than 12
With children ages 12 to 17 now eligible for COVID-19 vaccination, many families have jumped at the chance to protect their older kids from SARS-CoV-2 infection. However, what about children younger than 12? Pfizer is now starting another large scale study of the safety and efficacy of its COVID-19 immunization among kids ages 6 months to 11 years old. The study will include 4,500 children in the United States, Finland, Poland, and Spain. Study participants ages 5 to 11 will receive 10 micrograms of the vaccine and those ages 6 months to 5 years will receive 3 micrograms. The dose for those ages 12 and older is 30 micrograms. Click here to read more.